Category: pharmacology

Bogus Western blots lead to retraction of cancer paper

ejpharmA group of Italian researchers has retracted their 2013 paper on colorectal cancer because one of the authors, they, say, was tinkering with the data.

The article, “PBOX-15 induces apoptosis and improves the efficacy of oxaliplatin in human colorectal cancer cell lines,” appeared in the European Journal of Pharmacology in August. The first author was Giuseppina Gangemi, of the University of Salerno.

The paper purported to find that:

Continue reading Bogus Western blots lead to retraction of cancer paper

Pharmaceutical journal retracts antibiotics paper with dodgy data, with an unclear notice

aapsAAPS PharmSciTech, a journal of the American Association of Pharmaceutical Scientists, has retracted a 2013 paper by a group from India. The reason appears to be manipulated data, although the wording of the notice leaves that open to interpretation.

The article, “Design and Formulation Technique of a Novel Drug Delivery System for Azithromycin and Its Anti-Bacterial Activity Against Staphylococcus aureus,” was written by a trio of researchers at the Center for Nanobiotechnology at VIT University in Vellore.

The article, published online in June, purported to find that: Continue reading Pharmaceutical journal retracts antibiotics paper with dodgy data, with an unclear notice

And then there were none: Plagiarism forces retraction of metabolism paper with vanishing authors

N&MlogoNutrition & Metabolism has retracted a 2008 article by a dwindling group of researchers from Pakistan. We’d say it’s the equivalent of punting on first down, expect that’s what the editors probably should have done in the beginning.

As it happens, the journal seems to be guilty of delay of game in this case. As this blog post by Jeffrey Beall notes, allegations that the now-retracted paper was a verbatim copy of another article arose in 2010.

The abstract of the article, which is still available, reads: Continue reading And then there were none: Plagiarism forces retraction of metabolism paper with vanishing authors

“Not suitable in this context” means retraction in pharmacology journal

pbbPharmacology Biochemistry and Behavior had a curious retraction notice in September that we’re just now getting around to, but we think you’ll find it to have been worth the wait.

The article, “Interaction of Somatostatin Receptor-2 and Neuropeptide Y Receptor-1 in mice dorsal root ganglion neurons on the Pinch-Nerve injury model,” came from a group in Harbin, China, and Frieburg, Germany, and was published in April 2013.

According to the notice: Continue reading “Not suitable in this context” means retraction in pharmacology journal

Paper on over-the-counter drugs goes over the line in borrowing text

crraThe journal Clinical Research and Regulatory Affairs has retracted a 2012 article on over-the-counter drugs by a trio of pharmacy researchers in India who decided to “reproduce content to a high degree of similarity” from other sources.

Here’s how the retraction notice puts it: Continue reading Paper on over-the-counter drugs goes over the line in borrowing text

Duplicate submission costs authors two papers on Parkinson’s disease

neuropeptidecoverA group of pharmacology researchers in the UK has lost two papers after submitting effectively identical versions to different journals — and getting them accepted, of course — just a day apart.

The first article appeared on the British Journal of Pharmacology‘s website on July 10, 2012. It was titled “Exendin-4 reverts behavioural and neurochemicaldysfunction in a pre-motor rodent model of Parkinson’s disease with noradrenergic deficit.”

Paper 2 appeared in the journal Neuropeptides in October, although it has an online pub date of August 24, and was titled “Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson’s disease with combined noradrenergic and serotonergic lesions.”

Continue reading Duplicate submission costs authors two papers on Parkinson’s disease

Study plagiarizes so many other papers, retraction notice can’t list them all

j controlled releaseIn a new retraction notice, the Journal of Controlled Release is living up to its name.

The editor-in-chief has retracted a study that plagiarized “a large number” of papers, but only three are listed in the notice. Here’s the notice for “In situ-forming hydrogels for sustained ophthalmic drug delivery,” by Basavaraj K. Nanjawade, F.V. Manvi, and A.S. Manjappa, three researchers at India’s KLES’s College of Pharmacy, JN Medical College Campus, Karnataka: Continue reading Study plagiarizes so many other papers, retraction notice can’t list them all

Statins without prescription website paper retracted after company says it requires scripts, threatens suit

The authors of a paper on websites that sell cholesterol-lowering statin medications without prescriptions have retracted it. The move followed the threat of a lawsuit against the journal by a company included in the study that says it never dispenses sans a script.

Here’s the notice: Continue reading Statins without prescription website paper retracted after company says it requires scripts, threatens suit

JPET peeves: Paper withdrawn after drug company won’t disclose chemical structure

A group of researchers at the drug company ChemoCentryx is withdrawing a 2012 paper in the Journal of Pharmacology and Experimental Therapeutics over failure to appropriately identify the molecule they describe in the article.

The withdrawal notice tells the story: Continue reading JPET peeves: Paper withdrawn after drug company won’t disclose chemical structure